Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Adaptimmune Therapeutics

    NASDAQ: ADAP · Real-Time Price · USD
    0.28
    -0.00 (-1.06%)
    At close: Jun 09, 2025, 3:58 PM
    -1.06%
    Bid 0.28
    Market Cap 72.84M
    Revenue (ttm) 179.64M
    Net Income (ttm) -69.89M
    EPS (ttm) -0.3
    PE Ratio (ttm) -0.94
    Forward PE -2.04
    Analyst Buy
    Ask 0.32
    Volume 655,882
    Avg. Volume (20D) 1,843,711
    Open 0.30
    Previous Close 0.28
    Day's Range 0.28 - 0.30
    52-Week Range 0.20 - 1.48
    Beta 2.25

    About ADAP

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ADAP
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ADAP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -15.31%
    ADAP stock has given up its prior gain. Adaptimmun... Unlock content with Pro Subscription
    1 month ago
    -15.31%
    Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
    news image

    1 month ago · seekingalpha.com

    Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

    Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Ci...

    news image

    1 month ago · newsfilecorp.com

    Adaptimmune Reports Q1 Financial Results and Provides Business Update

    TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45...

    news image

    1 month ago · newsfilecorp.com

    Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

    news image

    2 months ago · seekingalpha.com

    Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

    Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Of...

    news image

    2 months ago · newsfilecorp.com

    Adaptimmune Provides Q4 and Full Year 2024 Business Update

    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submiss...

    news image

    3 months ago · newsfilecorp.com

    Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c...

    Add to Watchlist